Research Suggests Powerful Cancer Prevention Combo: GLP-1RAs and Progestins for Women at Risk Medical Dialogues
Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of …
Endometriosis, PCOS, adenomyosis, and dysmenorrhea are major illnesses. Hormonal as well as non-hormonal treatments were evaluated for COCs, progestins, GnRH analogues, LNG-IUS, relugolix, and adjunctive therapies. These treatments resulted in …
Endometriosis is a chronic, systemic, oestrogen-dependent disease with major impacts on pain, fertility and quality of life. This Society of Endometriosis and Uterine Disorders and American Institute for Minimally Invasive …
Endometriosis is a complex, estrogen-dependent disease with limited effective treatments that often focus on symptom management rather than addressing the underlying pathology. Current therapies, such as progestins and GnRH agonists, …
The reproductive microbiome plays a key role in disease progression and fertility in women with endometriosis. Vaginal and endometrial dysbiosis has been increasingly linked to inflammation, impaired reproductive outcomes, and …
GLP-1s Plus Progestins Tied to Lower Endometrial Cancer Risk Medscape
GLP-1 Receptor Agonists Combined with Progestins and Their Impact on Bioengineer.org
GLP-1 Receptor Agonists Combined with Progestins and Their Impact on BIOENGINEER.ORG
Hormonal therapy is the cornerstone of long-term endometriosis management, especially for women deferring surgery. In patients with comorbid migraine - a common, disabling condition - therapeutic choices must balance efficacy …